Article abstract


Nature Chemical Biology 2, 551 - 558 (2006)
Published online: 20 August 2006 | Corrected online: 22 May 2007 | doi:10.1038/nchembio815



There is a Corrigendum (July 2007) associated with this Article.

Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia

David Herman1, Kai Jenssen1, Ryan Burnett1, Elisabetta Soragni1, Susan L Perlman2 & Joel M Gottesfeld1


Expansion of GAAdotTTC triplets within an intron in FXN (the gene encoding frataxin) leads to transcription silencing, forming the molecular basis for the neurodegenerative disease Friedreich's ataxia. Gene silencing at expanded FXN alleles is accompanied by hypoacetylation of histones H3 and H4 and trimethylation of histone H3 at Lys9, observations that are consistent with a heterochromatin-mediated repression mechanism. We describe the synthesis and characterization of a class of histone deacetylase (HDAC) inhibitors that reverse FXN silencing in primary lymphocytes from individuals with Friedreich's ataxia. We show that these molecules directly affect the histones associated with FXN, increasing acetylation at particular lysine residues on histones H3 and H4 (H3K14, H4K5 and H4K12). This class of HDAC inhibitors may yield therapeutics for Friedreich's ataxia.

Top
  1. Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
  2. Department of Neurology, University of California School of Medicine, Los Angeles, California 90095, USA.

Correspondence to: Joel M Gottesfeld1 e-mail: joelg@scripps.edu

* CFI added

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Breaking the silence in Friedreich's ataxia

Nature Chemical Biology News and Views (01 Oct 2006)

Friedreich's in relief

Nature Genetics News and Views (01 Apr 1996)


Extra navigation

Subscribe to Nature Chemical Biology

Subscribe

Open Innovation Challenges

naturejobs